Alberico L Catapano
Alberico L Catapano is an expert in Cardiology at MultiMedica (Italy). As of October 2026, ScienceLeadR ranks Alberico L Catapano in the top 1% of experts worldwide for Hypercholesterolemia, Dyslipidemias and Hyperlipidemias. Alberico L Catapano has authored 1,092 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 2 of them ongoing. SLR score: 4,133 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Biochemistry - Nutrition
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1978 - 2026
Number : 1092
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| [Role of statin/ezetimibe fixed-dose combination in lipid risk management in the cardiovascular disease continuum]. PMID 42937206 — ezetimibe, cholesterol, ldl, cardiovascular diseases, risk management, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, nocebo effect | G Ital Cardiol (Rome) | 2026 | 0 |
| [From guidelines: cardiovascular risk stratification and therapeutic targets]. PMID 42937207 — ezetimibe, cholesterol, ldl, cardiovascular diseases, cholesterol, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, lipoprotein(a) | G Ital Cardiol (Rome) | 2026 | 0 |
| Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia. PMID 42709041 — cholesterol, ldl, safety, drug therapy, cholesterol, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, hypercholesterolemia | Expert Opin Pharmacother | 2026 | 0 |
| Correction: Identifying barriers to lipoprotein(a) testing in secondary cardiovascular prevention and co-designing implementation strategies: an Italian behavior change wheel-informed study. PMID 42936350 — research design, lipoproteins, lipoprotein(a), implementation science | Front Cardiovasc Med | 2026 | 0 |
| Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry. PMID 42149947 — registries, cholesterol, ldl, lipoproteins, cardiovascular diseases, cardiology, cholesterol, sex, diagnosis, therapeutics | Eur Heart J Top journal | 2026 | 0 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 6
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia NCT06832371 — hyperlipoproteinemia type ii, cholesterol, ldl, cardiovascular diseases, dyslipidemias, lipid metabolism disorders, cholesterol, atherosclerosis, therapeutics, genetic diseases, inborn, hypercholesterolemia, homozygous familial hypercholesterolemia, lipids | N/A | Active not recruiting | 2024 |
| Italian Digital Primary Cardiovascular Prevention Study NCT05339841 — diabetes mellitus, hypertension, life style, algorithms, mobile applications, risk factors, primary prevention, empowerment, hypercholesterolemia, digital health | N/A | Active not recruiting | 2022 |
LeadR Networks
Main global connection map